Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis

被引:4
作者
Hradilek, Pavel [1 ,2 ]
Revendova, Kamila Zondra [1 ,2 ]
Horakova, Jana [2 ]
Bunganic, Radovan [1 ,2 ]
Pelisek, Ondrej [3 ]
Zeman, David [4 ]
Hanzlikova, Pavla [5 ]
Kusnierova, Pavlina [6 ,7 ]
机构
[1] Univ Ostrava, Dept Clin Neurosci, Fac Med, Ostrava, Czech Republic
[2] Univ Hosp Ostrava, Dept Neurol, Ostrava, Czech Republic
[3] Masaryk Univ, Fac Med, Brno, Czech Republic
[4] Univ Hosp Brno, Dept Lab Med, Brno, Czech Republic
[5] Univ Ostrava, Dept Imaging Methods, Fac Med, Ostrava, Czech Republic
[6] Univ Hosp Ostrava, Inst Lab Med, Dept Clin Biochem, Ostrava, Czech Republic
[7] Univ Ostrava, Inst Lab Med, Fac Med, Ostrava, Czech Republic
来源
BIOMEDICAL PAPERS-OLOMOUC | 2023年 / 167卷 / 01期
关键词
multiple sclerosis; biomarkers; neurofilament light chain; CXCL13; clinical course; PROGNOSTIC MARKER; DISEASE-ACTIVITY; AXONAL DAMAGE; BIOMARKERS; DISABILITY; DIAGNOSIS; CRITERIA;
D O I
10.5507/bp.2023.002
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Aim. The aim of this study was to identify whether NfL and CXCL13 cerebrospinal fluid (CSF) concentrations at diagnostic lumbar puncture can predict the course of multiple sclerosis (MS) in terms of relapses, higher expanded disability status scale (EDSS) and magnetic resonance imaging (MRI) activity. Methods. We conducted a single-centre prospective observational cohort study at the MS center, University Hospital Ostrava, Czech Republic. CSF NfL (cNfL) and CXCL13 concentrations were examined (ELISA method) in patients with clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) at the time of diagnostic lumbar puncture. Results. A total of 44 patients with CIS or early RRMS were enrolled, 31 (70.5%) of whom were women. The median age at the time of CSF sampling was 31.21 years (IQR 25.43-39.32), and the follow-up period was 54.6 months (IQR 44.03-59.48). In the simple and multiple logistic regression models, CXCL13 levels did not predict relapses, MRI activity or EDSS > 2.5. Similarly, cNfL concentrations did not predict relapses or MRI activity in either model. In the multiple regression, higher cNfL levels were associated with reaching EDSS > 2.5 (odds ratio [OR] 1.002, 95% confidence interval [CI] 1.000 to 1.003). Conclusions. Our data did not confirm cNfL and/or CXCL13 CSF levels were predictive factors for disease activity such as relapses and MRI activity at the time of diagnostic lumbar puncture in patients with RRMS. While cNfL CSF levels predicted higher disability only after adjustment for other known risk factors, elevated CSF CXCL13 did not predict higher disability at all.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 37 条
  • [1] The potential of serum neurofilament as biomarker for multiple sclerosis
    Bittner, Stefan
    Oh, Jiwon
    Havrdova, Eva Kubala
    Tintore, Mar
    Zipp, Frauke
    [J]. BRAIN, 2021, 144 : 2954 - 2963
  • [2] Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
    Bjornevik, Kjetil
    Munger, Kassandra L.
    Cortese, Marianna
    Barro, Christian
    Healy, Brian C.
    Niebuhr, David W.
    Scher, Ann I.
    Kuhle, Jens
    Ascherio, Alberto
    [J]. JAMA NEUROLOGY, 2020, 77 (01) : 58 - 64
  • [3] Natalizumab in progressive MS Results of an open-label, phase 2A, proof-of-concept trial
    Christensen, Jeppe Romme
    Ratzer, Rikke
    Bornsen, Lars
    Lyksborg, Mark
    Garde, Ellen
    Dyrby, Tim B.
    Siebner, Hartwig R.
    Sorensen, Per S.
    Sellebjerg, Finn
    [J]. NEUROLOGY, 2014, 82 (17) : 1499 - 1507
  • [4] Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis
    DiSano, Krista D.
    Gilli, Francesca
    Pachner, Andrew R.
    [J]. MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (04)
  • [5] Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
    Disanto, Giulio
    Barro, Christian
    Benkert, Pascal
    Naegelin, Yvonne
    Schadelin, Sabine
    Giardiello, Antonella
    Zecca, Chiara
    Blennow, Kaj
    Zetterberg, Henrik
    Leppert, David
    Kappos, Ludwig
    Gobbi, Claudio
    Kuhle, Jens
    [J]. ANNALS OF NEUROLOGY, 2017, 81 (06) : 857 - 870
  • [6] Multiple sclerosis - a review
    Dobson, R.
    Giovannoni, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 (01) : 27 - 40
  • [7] MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
    Filippi, Massimo
    Rocca, Maria A.
    Ciccarelli, Olga
    De Stefano, Nicola
    Evangelou, Nikos
    Kappos, Ludwig
    Rovira, Alex
    Sastre-Garriga, Jaume
    Tintore, Mar
    Frederiksen, Jette L.
    Gasperini, Claudio
    Palace, Jacqueline
    Reich, Daniel S.
    Banwell, Brenda
    Montalban, Xavier
    Barkhof, Frederik
    [J]. LANCET NEUROLOGY, 2016, 15 (03) : 292 - 303
  • [8] Foroughi AA, 2017, NEURORADIOL J, V30, DOI 10.1177/1971400916678224
  • [9] Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
    Gunnarsson, Martin
    Malmestrom, Clas
    Axelsson, Markus
    Sundstrom, Peter
    Dahle, Charlotte
    Vrethem, Magnus
    Olsson, Tomas
    Piehl, Fredrik
    Norgren, Niklas
    Rosengren, Lars
    Svenningsson, Anders
    Lycke, Jan
    [J]. ANNALS OF NEUROLOGY, 2011, 69 (01) : 83 - 89
  • [10] Biomarkers in multiple sclerosis
    Housley, William J.
    Pitt, David
    Hafler, David A.
    [J]. CLINICAL IMMUNOLOGY, 2015, 161 (01) : 51 - 58